



April 27, 2026

Ref:- GH/2026-27/EXCH/04

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

**Sub:** Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('GHL') at its meeting held today i.e. *Monday, April 27, 2026*, has *inter alia*, approved execution of a Business Transfer Agreement (BTA) for a 79 bedded Cancer Care Hospital in Indore, assignment of lease deed as part of the transaction and execution of fresh lease for an additional 1,700 sqft of the space within the facility. The target hospital is in close proximity to Company's existing facility in Indore.

The details as required under Regulation 30 of Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30th January 2026, are enclosed as Exhibit.

The meeting of the Board of Directors commenced at 2.00 P.M. and concluded at 2:35 P.M.


This is for your information and records.

Thanking You,

**For Global Health Limited**

**Rahul Ranjan**  
Company Secretary & Compliance Officer  
M. No. A17035

Encl: a/a



**Details as required under Schedule III of Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 are as under:**

**a) Acquisition**

S. No	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Business Undertaking in form of Hospital currently owned and operated by Asian Institute of Oncology Private Limited (AIOPL) at Indore. Size and Turnover: 79 Bedded Advance Super Specialty Hospital primarily engaged in providing oncology services. Turnover of the hospital for FY 2024-25 was Rs. 19.9 million.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No  Asian Institute of Oncology Private Limited is not a related party and hence the transaction does not fall within the ambit of related party transaction.  None of promoter/promoter group/group companies have any interest in the said transaction.
3.	Industry to which the entity being acquired belongs;	Healthcare
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The target hospital is a 79 bedded cancer care hospital. The hospital shall be added to Medanta network on consummation of the transaction subject to necessary statutory and customary approvals.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	The transaction is subject to necessary statutory and customary approvals primarily related to change of ownership.
6.	Indicative time period for completion of the acquisition;	September 30, 2026 is the long stop date under BTA, however it is expected that the acquisition will be completed much prior to that date.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Medanta to pay Rs. 30 crores as consideration for transfer of business under BTA.



# Global Health L i m i t e d

9.	Percentage of shareholding / control acquired and / or number of shares acquired	The Company will acquire 100% control over the business undertaking.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	NA as only Business Undertaking is acquired and no legal entity is acquired as detailed here-in above.

## b) Capacity Addition

S. No	Particulars	Details
1.	Existing capacity	As on March 31, 2026, Medanta has existing capacity of 3,579 bed.
2.	Existing capacity utilization	Currently, Medanta Hospitals are operating in Gurugram, Indore, Ranchi, Lucknow, Patna and Noida.
3.	Proposed capacity addition	A 79 bed hospital at Indore is proposed to be added to GHIL under the BTA.
4.	Period within which the proposed capacity is to be added	The target hospital is a 79 bedded cancer care hospital. The hospital shall be added to Medanta network on consummation of the transaction subject to necessary statutory and customary approvals.
5.	Investment required	Medanta to pay Rs. 30 crores as consideration for transfer of business under BTA.
6.	Mode of financing	To be funded by a combination of internal accruals and debt funding.
7.	Rationale	<p>The hospital is strategically located just 500 meters from Medanta Indore existing facility and will enable seamless integration and operational synergies.</p> <p>The target hospital has been purpose-built with a primary focus on cancer care.</p> <p>The transaction will allow Medanta to further strengthen its presence in the region, enhance its portfolio of tertiary and quaternary care services, and fill the existing specialty gap in oncology.</p>

